Literature DB >> 22177943

Investigation of autoantibody profiles for cerebrospinal fluid biomarker discovery in patients with relapsing-remitting multiple sclerosis.

Natascha Helena Beyer1, Angelika Lueking, Axel Kowald, Jette Lautrup Frederiksen, Niels H H Heegaard.   

Abstract

Using the UNIarray® marker technology platform, cerebrospinal fluid immunoglobulin G reactivities of 15 controls and 17 RRMS patients against human recombinant proteins were investigated. Patient cerebrospinal fluids were oligoclonal band positive and reactivities were compared to that of sex- and age-matched controls. We hereby aimed at the characterization of autoreactivity in patients with RRMS. Differences in autoreactivities between control and RRMS samples were identified comprising autoantigens identified in this study only and previously reported autoantigens as well. A combination of the 10-15 most significant proteins may be investigated further as autoantigens for diagnostic purposes. Additional investigations may include minimizing the number of proteins used in such diagnostic tests.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22177943     DOI: 10.1016/j.jneuroim.2011.08.013

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  10 in total

1.  Anoctamin 2 identified as an autoimmune target in multiple sclerosis.

Authors:  Burcu Ayoglu; Nicholas Mitsios; Ingrid Kockum; Mohsen Khademi; Arash Zandian; Ronald Sjöberg; Björn Forsström; Johan Bredenberg; Izaura Lima Bomfim; Erik Holmgren; Hans Grönlund; André Ortlieb Guerreiro-Cacais; Nada Abdelmagid; Mathias Uhlén; Tim Waterboer; Lars Alfredsson; Jan Mulder; Jochen M Schwenk; Tomas Olsson; Peter Nilsson
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-09       Impact factor: 11.205

2.  Serum profiling using protein microarrays to identify disease related antigens.

Authors:  Donald Sharon; Michael Snyder
Journal:  Methods Mol Biol       Date:  2014

3.  Protein array-based profiling of CSF identifies RBPJ as an autoantigen in multiple sclerosis.

Authors:  Luis Querol; Pamela L Clark; Mary A Bailey; Chris Cotsapas; Anne H Cross; David A Hafler; Steven H Kleinstein; Jae-Yun Lee; Gur Yaari; Simon N Willis; Kevin C O'Connor
Journal:  Neurology       Date:  2013-08-06       Impact factor: 9.910

4.  High-Density Peptide Microarray Analysis of IgG Autoantibody Reactivities in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients.

Authors:  Michael Hecker; Brit Fitzner; Matthias Wendt; Peter Lorenz; Kristin Flechtner; Felix Steinbeck; Ina Schröder; Hans-Jürgen Thiesen; Uwe Klaus Zettl
Journal:  Mol Cell Proteomics       Date:  2016-02-01       Impact factor: 5.911

5.  Uncovering cryptic glycan markers in multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE).

Authors:  Denong Wang; Roopa Bhat; Raymond A Sobel; Wei Huang; Lai-Xi Wang; Tomas Olsson; Lawrence Steinman
Journal:  Drug Dev Res       Date:  2014-03-11       Impact factor: 4.360

Review 6.  Does disease-irrelevant intrathecal synthesis in multiple sclerosis make sense in the light of tertiary lymphoid organs?

Authors:  Mickael Bonnan
Journal:  Front Neurol       Date:  2014-03-11       Impact factor: 4.003

7.  Serum Autoantibodies in Chronic Prostate Inflammation in Prostate Cancer Patients.

Authors:  Bettina Schlick; Petra Massoner; Angelika Lueking; Pornpimol Charoentong; Mirjam Blattner; Georg Schaefer; Klaus Marquart; Carmen Theek; Peter Amersdorfer; Dirk Zielinski; Matthias Kirchner; Zlatko Trajanoski; Mark A Rubin; Stefan Müllner; Peter Schulz-Knappe; Helmut Klocker
Journal:  PLoS One       Date:  2016-02-10       Impact factor: 3.240

8.  Investigating the Antigen Specificity of Multiple Sclerosis Central Nervous System-Derived Immunoglobulins.

Authors:  Simon N Willis; Panos Stathopoulos; Anne Chastre; Shannon D Compton; David A Hafler; Kevin C O'Connor
Journal:  Front Immunol       Date:  2015-11-25       Impact factor: 7.561

9.  Autoantibody profiling in multiple sclerosis using arrays of human protein fragments.

Authors:  Burcu Ayoglu; Anna Häggmark; Mohsen Khademi; Tomas Olsson; Mathias Uhlén; Jochen M Schwenk; Peter Nilsson
Journal:  Mol Cell Proteomics       Date:  2013-06-03       Impact factor: 5.911

Review 10.  Biomarkers of therapeutic response in multiple sclerosis: current status.

Authors:  Violaine K Harris; Saud A Sadiq
Journal:  Mol Diagn Ther       Date:  2014-12       Impact factor: 4.074

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.